Amphastar appoints David Gaugh as Class I director; board size increased to 11

Amphastar Pharmaceuticals, Inc.

Board increased authorized directors from 10 to 11 and appointed David Gaugh effective July 18, 2025.
Gaugh will serve until the 2026 annual meeting; no committee assignments at this time.
Initial compensation: $260,000 aggregate grant date fair value, 50% RSUs and 50% stock options, vesting on first anniversary.
Board determined Gaugh is independent under Nasdaq listing standards; no reportable transactions or arrangements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.